Posts

Showing posts with the label Undifferentiated Pleomorphic Sarcoma market outlook

Undifferentiated Pleomorphic Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Undifferentiated Pleomorphic Sarcoma (UPS) is a rare and aggressive type of sarcoma that can originate in any body part, including soft tissue and bone. The most common sites of involvement are the lower extremities, particularly the thigh, upper arms, retroperitoneum, viscera, head, and neck (in childhood cases). High local recurrence rates and significant metastasis typically characterize it. Symptoms of UPS may include swelling, mass, pain, pathological fractures, and systemic features such as anorexia, malaise, fever, and weight loss. The tumor is diagnosed in individuals between 60 and 70. Treatment for UPS typically involves wide surgical excision, radiation, and sometimes amputation. Adjuvant radiotherapy is often given for high-grade, large, deep-seated tumors, in limb-sparing surgeries, and when negative margins are not obtained. The overall 5-year survival rate for UPS ranges from 48% for patients with head and neck tumors to 77% for patients with tumors arising on th...

Undifferentiated Pleomorphic Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
Undifferentiated Pleomorphic Sarcoma (UPS) is a rare and aggressive type of sarcoma that can originate in any body part, including soft tissue and bone. The tumor is most commonly diagnosed in individuals between the ages of 60 and 70, with the most common sites of involvement being the lower extremities, particularly the thigh, upper arms, retroperitoneum, viscera, head, and neck (in childhood cases). High local recurrence rates and significant metastasis typically characterize it. Symptoms of UPS may include swelling, mass, pain, pathological fractures, and systemic features such as anorexia, malaise, fever, and weight loss. Treatment for UPS typically involves wide surgical excision; sometimes, amputation may be necessary to remove the entire lesion. Adjuvant radiotherapy is often given for high-grade, large, deep-seated tumors, in limb-sparing surgeries, and when negative margins are not obtained. Primary radiation therapy may be an option for inoperable sarcomas, but chemotherapy ...